New drug cocktail shows promise for Tough-to-Treat colon cancer
NCT ID NCT04109924
First seen Feb 10, 2026 · Last updated May 21, 2026 · Updated 13 times
Summary
This study tested a combination of three drugs (TAS-102, irinotecan, and bevacizumab) in 42 people with advanced colorectal cancer that had already been treated before. The goal was to see if this mix could slow or stop cancer growth better than standard options. Participants received the drugs through IV infusions and pills over two-week cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III RECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Conditions
Explore the condition pages connected to this study.